NR565 ADVANCED PHARMACOLOGY MIDTERM
2026/2027 | Already Rated A Review | Chamberlain | Pass
Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (20 Questions)
Q1: A 68-year-old patient with chronic heart failure is prescribed oral furosemide 40 mg
daily. The nurse practitioner recognizes that this medication has low bioavailability due
to extensive first-pass metabolism. Which pharmacokinetic principle best explains why
the oral dose is significantly higher than the intravenous dose for the same therapeutic
effect?
A. The drug undergoes enterohepatic recirculation, increasing its half-life
B. The liver metabolizes a large portion of the drug before it reaches systemic
circulation
C. The drug has a large volume of distribution and distributes extensively into adipose
tissue
D. The drug is primarily excreted unchanged by the kidneys
C. The liver metabolizes a large portion of the drug before it reaches systemic
circulation [CORRECT]
Correct Answer: C
Rationale: First-pass metabolism refers to the hepatic extraction of drug from portal
circulation before it reaches systemic circulation, significantly reducing bioavailability
for orally administered drugs. Furosemide has approximately 50% bioavailability orally
compared to IV administration, necessitating higher oral doses. Option A describes
enterohepatic recirculation, which is not the primary issue with furosemide. Option D is
incorrect because furosemide is partially metabolized and partially excreted unchanged.
Option C describes volume of distribution, which does not explain the oral-IV dose
discrepancy.
Q2: A nurse practitioner is monitoring a patient receiving phenytoin for seizure control.
The patient recently started taking ciprofloxacin for a urinary tract infection. The NP
,recognizes that ciprofloxacin is a CYP1A2 inhibitor. Which clinical concern is most
appropriate regarding this drug interaction?
A. Phenytoin levels may decrease, increasing seizure risk
B. Phenytoin levels may increase, increasing risk of toxicity
C. Ciprofloxacin absorption will be reduced by phenytoin chelation
D. The interaction is clinically insignificant and requires no monitoring
B. Phenytoin levels may increase, increasing risk of toxicity [CORRECT]
Correct Answer: B
Rationale: Ciprofloxacin inhibits CYP1A2 and can also inhibit CYP2C9/2C19, which are
primary metabolic pathways for phenytoin. Inhibition of these enzymes decreases
phenytoin metabolism, leading to increased plasma concentrations and risk of CNS
toxicity, including nystagmus, ataxia, and sedation. Option A is incorrect because
inhibition increases, not decreases, substrate drug levels. Option C describes a different
interaction mechanism (chelation) not applicable here. Option D is dangerous as this
interaction requires therapeutic drug monitoring.
Q3: A patient with end-stage renal disease is prescribed a medication that is 90%
eliminated by glomerular filtration. The NP calculates the creatinine clearance at 15
mL/min. According to pharmacokinetic principles, what is the most appropriate
prescribing action?
A. Increase the dosing frequency to maintain therapeutic levels
B. Decrease the dose or extend the dosing interval to prevent accumulation
C. No dose adjustment is needed because tubular secretion compensates for reduced
GFR
D. Switch to the intravenous route to bypass renal elimination
B. Decrease the dose or extend the dosing interval to prevent accumulation [CORRECT]
Correct Answer: B
Rationale: When renal clearance is severely impaired (CrCl <30 mL/min), drugs primarily
eliminated by glomerular filtration accumulate, increasing half-life and risk of toxicity.
Dose reduction or interval extension maintains therapeutic concentrations while
preventing accumulation. Option A would worsen toxicity. Option C is incorrect because
tubular secretion does not compensate for lost glomerular filtration. Option D does not
change the elimination pathway and offers no advantage for renally cleared drugs.
,Q4: A 45-year-old patient asks why their daily warfarin dose varies while their friend's
dose remains constant. The NP explains that warfarin metabolism involves CYP2C9,
which demonstrates genetic polymorphism. Which statement best describes the
clinical significance of CYP2C9 polymorphisms?
A. All patients metabolize warfarin at identical rates regardless of genetic variation
B. Poor metabolizers require lower warfarin doses and have increased bleeding risk at
standard doses
C. Ultra-rapid metabolizers are at higher risk for bleeding complications
D. Genetic testing is required by FDA before initiating all patients on warfarin
B. Poor metabolizers require lower warfarin doses and have increased bleeding risk at
standard doses [CORRECT]
Correct Answer: B
Rationale: CYP2C9 polymorphisms result in poor metabolizer phenotypes (*2 and *3
alleles) that significantly reduce warfarin metabolism, requiring 30-50% lower doses to
achieve therapeutic INR and avoid hemorrhage. Option A is incorrect as
pharmacogenomics demonstrates significant interindividual variability. Option C is
reversed—ultra-rapid metabolizers require higher doses and are at risk for
subtherapeutic anticoagulation. Option D is incorrect; while genetic testing is
recommended, it is not FDA-mandated for all patients.
Q5: A patient receiving morphine patient-controlled analgesia reports adequate pain
control but experiences significant sedation. The NP understands that
morphine-6-glucuronide (M6G), an active metabolite, accumulates in patients with renal
impairment. Which phase of drug metabolism produces this active metabolite?
A. Phase I oxidation via CYP3A4
B. Phase II glucuronidation via UDP-glucuronosyltransferase enzymes
C. Phase I reduction via CYP2D6
D. Phase II acetylation via N-acetyltransferase
B. Phase II glucuronidation via UDP-glucuronosyltransferase enzymes [CORRECT]
Correct Answer: B
Rationale: Morphine undergoes Phase II conjugation via UDP-glucuronosyltransferase
(UGT) 2B7 to form morphine-6-glucuronide (M6G), which has greater mu-opioid receptor
affinity than the parent drug and accumulates in renal failure, causing respiratory
depression and sedation. Option A describes Phase I oxidation, which is not the primary
, pathway for morphine. Option C incorrectly identifies CYP2D6, which is not involved in
morphine metabolism. Option D describes acetylation, which is not applicable to
morphine metabolism.
Q6: A nurse practitioner is teaching a patient about their new prescription for
atorvastatin. The patient mentions they drink grapefruit juice daily. Which
pharmacokinetic interaction should the NP emphasize?
A. Grapefruit juice inhibits intestinal CYP3A4 and P-glycoprotein, increasing statin
bioavailability and risk of myopathy
B. Grapefruit juice induces hepatic CYP3A4, decreasing statin effectiveness
C. Grapefruit juice chelates atorvastatin in the GI tract, reducing absorption
D. Grapefruit juice displaces atorvastatin from albumin binding sites, increasing free
drug concentration
A. Grapefruit juice inhibits intestinal CYP3A4 and P-glycoprotein, increasing statin
bioavailability and risk of myopathy [CORRECT]
Correct Answer: A
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal
CYP3A4 and P-glycoprotein efflux transporters, significantly increasing bioavailability of
CYP3A4 substrates like atorvastatin, simvastatin, and lovastatin, thereby increasing risk
of rhabdomyolysis. Option B is reversed—grapefruit inhibits, not induces. Option C
describes chelation, which does not occur with grapefruit. Option D describes protein
displacement, which is not the mechanism of this interaction.
Q7: A patient with schizophrenia is prescribed aripiprazole, a partial dopamine agonist.
The NP explains that this medication has unique pharmacodynamic properties
compared to haloperidol, a full antagonist. Which statement best describes the
pharmacodynamic advantage of aripiprazole?
A. It acts as a functional antagonist in hyperdopaminergic states and functional agonist
in hypodopaminergic states
B. It completely blocks all dopamine receptors regardless of endogenous dopamine
levels
C. It has no intrinsic activity and requires endogenous dopamine to produce any effect
D. It only activates dopamine receptors in the nigrostriatal pathway
A. It acts as a functional antagonist in hyperdopaminergic states and functional agonist
in hypodopaminergic states [CORRECT]
Correct Answer: A
2026/2027 | Already Rated A Review | Chamberlain | Pass
Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (20 Questions)
Q1: A 68-year-old patient with chronic heart failure is prescribed oral furosemide 40 mg
daily. The nurse practitioner recognizes that this medication has low bioavailability due
to extensive first-pass metabolism. Which pharmacokinetic principle best explains why
the oral dose is significantly higher than the intravenous dose for the same therapeutic
effect?
A. The drug undergoes enterohepatic recirculation, increasing its half-life
B. The liver metabolizes a large portion of the drug before it reaches systemic
circulation
C. The drug has a large volume of distribution and distributes extensively into adipose
tissue
D. The drug is primarily excreted unchanged by the kidneys
C. The liver metabolizes a large portion of the drug before it reaches systemic
circulation [CORRECT]
Correct Answer: C
Rationale: First-pass metabolism refers to the hepatic extraction of drug from portal
circulation before it reaches systemic circulation, significantly reducing bioavailability
for orally administered drugs. Furosemide has approximately 50% bioavailability orally
compared to IV administration, necessitating higher oral doses. Option A describes
enterohepatic recirculation, which is not the primary issue with furosemide. Option D is
incorrect because furosemide is partially metabolized and partially excreted unchanged.
Option C describes volume of distribution, which does not explain the oral-IV dose
discrepancy.
Q2: A nurse practitioner is monitoring a patient receiving phenytoin for seizure control.
The patient recently started taking ciprofloxacin for a urinary tract infection. The NP
,recognizes that ciprofloxacin is a CYP1A2 inhibitor. Which clinical concern is most
appropriate regarding this drug interaction?
A. Phenytoin levels may decrease, increasing seizure risk
B. Phenytoin levels may increase, increasing risk of toxicity
C. Ciprofloxacin absorption will be reduced by phenytoin chelation
D. The interaction is clinically insignificant and requires no monitoring
B. Phenytoin levels may increase, increasing risk of toxicity [CORRECT]
Correct Answer: B
Rationale: Ciprofloxacin inhibits CYP1A2 and can also inhibit CYP2C9/2C19, which are
primary metabolic pathways for phenytoin. Inhibition of these enzymes decreases
phenytoin metabolism, leading to increased plasma concentrations and risk of CNS
toxicity, including nystagmus, ataxia, and sedation. Option A is incorrect because
inhibition increases, not decreases, substrate drug levels. Option C describes a different
interaction mechanism (chelation) not applicable here. Option D is dangerous as this
interaction requires therapeutic drug monitoring.
Q3: A patient with end-stage renal disease is prescribed a medication that is 90%
eliminated by glomerular filtration. The NP calculates the creatinine clearance at 15
mL/min. According to pharmacokinetic principles, what is the most appropriate
prescribing action?
A. Increase the dosing frequency to maintain therapeutic levels
B. Decrease the dose or extend the dosing interval to prevent accumulation
C. No dose adjustment is needed because tubular secretion compensates for reduced
GFR
D. Switch to the intravenous route to bypass renal elimination
B. Decrease the dose or extend the dosing interval to prevent accumulation [CORRECT]
Correct Answer: B
Rationale: When renal clearance is severely impaired (CrCl <30 mL/min), drugs primarily
eliminated by glomerular filtration accumulate, increasing half-life and risk of toxicity.
Dose reduction or interval extension maintains therapeutic concentrations while
preventing accumulation. Option A would worsen toxicity. Option C is incorrect because
tubular secretion does not compensate for lost glomerular filtration. Option D does not
change the elimination pathway and offers no advantage for renally cleared drugs.
,Q4: A 45-year-old patient asks why their daily warfarin dose varies while their friend's
dose remains constant. The NP explains that warfarin metabolism involves CYP2C9,
which demonstrates genetic polymorphism. Which statement best describes the
clinical significance of CYP2C9 polymorphisms?
A. All patients metabolize warfarin at identical rates regardless of genetic variation
B. Poor metabolizers require lower warfarin doses and have increased bleeding risk at
standard doses
C. Ultra-rapid metabolizers are at higher risk for bleeding complications
D. Genetic testing is required by FDA before initiating all patients on warfarin
B. Poor metabolizers require lower warfarin doses and have increased bleeding risk at
standard doses [CORRECT]
Correct Answer: B
Rationale: CYP2C9 polymorphisms result in poor metabolizer phenotypes (*2 and *3
alleles) that significantly reduce warfarin metabolism, requiring 30-50% lower doses to
achieve therapeutic INR and avoid hemorrhage. Option A is incorrect as
pharmacogenomics demonstrates significant interindividual variability. Option C is
reversed—ultra-rapid metabolizers require higher doses and are at risk for
subtherapeutic anticoagulation. Option D is incorrect; while genetic testing is
recommended, it is not FDA-mandated for all patients.
Q5: A patient receiving morphine patient-controlled analgesia reports adequate pain
control but experiences significant sedation. The NP understands that
morphine-6-glucuronide (M6G), an active metabolite, accumulates in patients with renal
impairment. Which phase of drug metabolism produces this active metabolite?
A. Phase I oxidation via CYP3A4
B. Phase II glucuronidation via UDP-glucuronosyltransferase enzymes
C. Phase I reduction via CYP2D6
D. Phase II acetylation via N-acetyltransferase
B. Phase II glucuronidation via UDP-glucuronosyltransferase enzymes [CORRECT]
Correct Answer: B
Rationale: Morphine undergoes Phase II conjugation via UDP-glucuronosyltransferase
(UGT) 2B7 to form morphine-6-glucuronide (M6G), which has greater mu-opioid receptor
affinity than the parent drug and accumulates in renal failure, causing respiratory
depression and sedation. Option A describes Phase I oxidation, which is not the primary
, pathway for morphine. Option C incorrectly identifies CYP2D6, which is not involved in
morphine metabolism. Option D describes acetylation, which is not applicable to
morphine metabolism.
Q6: A nurse practitioner is teaching a patient about their new prescription for
atorvastatin. The patient mentions they drink grapefruit juice daily. Which
pharmacokinetic interaction should the NP emphasize?
A. Grapefruit juice inhibits intestinal CYP3A4 and P-glycoprotein, increasing statin
bioavailability and risk of myopathy
B. Grapefruit juice induces hepatic CYP3A4, decreasing statin effectiveness
C. Grapefruit juice chelates atorvastatin in the GI tract, reducing absorption
D. Grapefruit juice displaces atorvastatin from albumin binding sites, increasing free
drug concentration
A. Grapefruit juice inhibits intestinal CYP3A4 and P-glycoprotein, increasing statin
bioavailability and risk of myopathy [CORRECT]
Correct Answer: A
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal
CYP3A4 and P-glycoprotein efflux transporters, significantly increasing bioavailability of
CYP3A4 substrates like atorvastatin, simvastatin, and lovastatin, thereby increasing risk
of rhabdomyolysis. Option B is reversed—grapefruit inhibits, not induces. Option C
describes chelation, which does not occur with grapefruit. Option D describes protein
displacement, which is not the mechanism of this interaction.
Q7: A patient with schizophrenia is prescribed aripiprazole, a partial dopamine agonist.
The NP explains that this medication has unique pharmacodynamic properties
compared to haloperidol, a full antagonist. Which statement best describes the
pharmacodynamic advantage of aripiprazole?
A. It acts as a functional antagonist in hyperdopaminergic states and functional agonist
in hypodopaminergic states
B. It completely blocks all dopamine receptors regardless of endogenous dopamine
levels
C. It has no intrinsic activity and requires endogenous dopamine to produce any effect
D. It only activates dopamine receptors in the nigrostriatal pathway
A. It acts as a functional antagonist in hyperdopaminergic states and functional agonist
in hypodopaminergic states [CORRECT]
Correct Answer: A
